1
|
Marsden AJ, Riley DRJ, Birkett S, Rodriguez-Barucg Q, Guinn BA, Carroll S, Ingle L, Sathyapalan T, Beltran-Alvarez P. Love is in the hair: arginine methylation of human hair proteins as novel cardiovascular biomarkers. Amino Acids 2022; 54:591-600. [PMID: 34181092 PMCID: PMC9117359 DOI: 10.1007/s00726-021-03024-5] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2021] [Accepted: 06/17/2021] [Indexed: 12/25/2022]
Abstract
Cardiovascular disease is the major cause of death worldwide. Extensive cardiovascular biomarkers are available using blood tests but very few, if any, investigations have described non-invasive tests for cardiovascular biomarkers based on readily available hair samples. Here we show, first, that human hair proteins are post-translationally modified by arginine methylation (ArgMe). Using western blot, proteomic data mining and mass spectrometry, we identify several ArgMe events in hair proteins and we show that keratin-83 is extensively modified by ArgMe in the human hair. Second, using a preliminary cohort (n = 18) of heterogenous healthy donors, we show that the levels of protein ArgMe in hair correlate with serum concentrations of a well-established cardiovascular biomarker, asymmetric dimethylarginine (ADMA). Compared to blood collection, hair sampling is cheaper, simpler, requires minimal training and carries less health and safety and ethical risks. For these reasons, developing the potential of hair protein ArgMe as clinically useful cardiovascular biomarkers through further research could be useful in future prevention and diagnosis of cardiovascular disease.
Collapse
Affiliation(s)
| | - David R J Riley
- Department of Biomedical Sciences, University of Hull, Cottingham Rd, Hull, HU6 7RX, UK
| | - Stefan Birkett
- Department of Sport, Health and Exercise Science, University of Hull, Hull, UK
- School of Sport and Health Sciences, University of Central Lancashire, Preston, UK
| | | | - Barbara-Ann Guinn
- Department of Biomedical Sciences, University of Hull, Cottingham Rd, Hull, HU6 7RX, UK
| | - Sean Carroll
- Department of Sport, Health and Exercise Science, University of Hull, Hull, UK
| | - Lee Ingle
- Department of Sport, Health and Exercise Science, University of Hull, Hull, UK
| | - Thozhukat Sathyapalan
- Academic Endocrinology, Diabetes and Metabolism, Hull York Medical School, University of Hull, Hull, UK
| | - Pedro Beltran-Alvarez
- Department of Biomedical Sciences, University of Hull, Cottingham Rd, Hull, HU6 7RX, UK.
| |
Collapse
|
2
|
Hu F, Yu Y, Lu F, Cheng X. Knockdown of transient receptor potential melastatin 2 reduces renal fibrosis and inflammation by blocking transforming growth factor-β1-activated JNK1 activation in diabetic mice. Aging (Albany NY) 2021; 13:24605-24620. [PMID: 34845114 PMCID: PMC8660601 DOI: 10.18632/aging.203694] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2021] [Accepted: 10/27/2021] [Indexed: 12/20/2022]
Abstract
BACKGROUND Diabetic nephropathy is a major complication of diabetes. We explore the protective effect of TRPM2 knockdown on the progression of diabetic nephropathy. METHODS A type 2 diabetes animal model was established in C57BL/6N mice by long-term high-fat diet (HFD) feeding combined with a single injection of 100 mg/kg streptozotocin (STZ). Genetic knockdown of TRPM2 in mouse kidneys was accomplished by the intravenous injection via the tail vein of adeno-associated virus type 2 carrying TRPM2 shRNA. RESULTS Mice with HFD/STZ-induced diabetes exhibited kidney dysfunction, as demonstrated by increased blood creatinine and urea nitrogen levels, accompanied by glomerulus derangement, tubule damage and extracellular matrix deposition in the interstitium. The protein expression of TRPM2, transforming growth factor-β1 (TGF-β1), connective tissue growth factor, α-smooth muscles actin, fibronectin, collagen I and collagen III, and the mRNA expression and contents of inflammatory factors, including interleukin-1β, interleukin-6, interferon-α, tumour necrosis factor -α and monocyte chemotactic protein -1, were significantly elevated in the renal tissues of the HFD/STZ-induced diabetes group compared to those of the two control groups. Furthermore, fluorescent staining of TRPM2 was markedly increased in the renal tubular epithelial cells from diabetic mice. Knockdown of TRPM2 significantly attenuated HFD/STZ-induced renal inflammatory responses and fibrosis, which was accompanied by activation of TGF-β1-activated c-Jun N-terminal protein kinase-1 (JNK1) signalling. JNK1 inactivation reversed hyperglycaemia-induced fibrosis and inflammation in HK-2 cells. CONCLUSION TRPM2 silencing significantly attenuated fibrosis and inflammation in the kidneys of mice with HFD/STZ-induced diabetes, which was largely achieved via the inhibition of TGF-β1-activated JNK1 activation.
Collapse
Affiliation(s)
- Feng Hu
- The Department of Cardiovascular Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, China
| | - Yun Yu
- The Department of Cardiovascular Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, China
| | - Feng Lu
- The Department of Cardiothoracic Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China
| | - Xiaoshu Cheng
- The Department of Cardiovascular Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, China
| |
Collapse
|
3
|
Reda A, El-Safty SA, Selim MM, Shenashen MA. Optical glucose biosensor built-in disposable strips and wearable electronic devices. Biosens Bioelectron 2021; 185:113237. [PMID: 33932881 DOI: 10.1016/j.bios.2021.113237] [Citation(s) in RCA: 18] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2020] [Revised: 01/25/2021] [Accepted: 04/06/2021] [Indexed: 01/19/2023]
Abstract
On-demand screening, real-time monitoring and rapid diagnosis of ubiquitous diseases, such as diabetes, at early stages are indispensable in personalised treatment. Emerging impacts of nano/microscale materials on optical and portable biosensor strips and devices have become increasingly important in the remarkable development of sensitive visualisation (i.e. visible inspection by the human eye) assays, low-cost analyses and personalised home testing of patients with diabetes. With the increasing public attention regarding the self-monitoring of diabetes, the development of visual readout, easy-to-use and wearable biosensors has gained considerable interest. Our comprehensive review bridges the practical assessment gap between optical bio-visualisation assays, disposable test strips, sensor array designs and full integration into flexible skin-based or contact lens devices with the on-site wireless signal transmission of glucose detection in physiological fluids. To date, the fully modulated integration of nano/microscale optical biosensors into wearable electronic devices, such as smartphones, is critical to prolong periods of indoor and outdoor clinical diagnostics. Focus should be given to the improvements of invasive, wireless and portable sensing technologies to improve the applicability and reliability of screen display, continuous monitoring, dynamic data visualisation, online acquisition and self and in-home healthcare management of patients with diabetes.
Collapse
Affiliation(s)
- Abdullah Reda
- National Institute for Materials Science (NIMS), Sengen 1-2-1, Tsukuba, Ibaraki, 305-0047, Japan
| | - Sherif A El-Safty
- National Institute for Materials Science (NIMS), Sengen 1-2-1, Tsukuba, Ibaraki, 305-0047, Japan.
| | - Mahmoud M Selim
- Prince Sattam Bin Abdulaziz University, P. O. Box 173, Al-Kharj, 11942, Saudi Arabia
| | - Mohamed A Shenashen
- National Institute for Materials Science (NIMS), Sengen 1-2-1, Tsukuba, Ibaraki, 305-0047, Japan
| |
Collapse
|
4
|
Lee Y, Mehrotra P, Basile D, Ullah M, Singh A, Skill N, Younes ST, Sasser J, Shekhar A, Singh J. Specific Lowering of Asymmetric Dimethylarginine by Pharmacological Dimethylarginine Dimethylaminohydrolase Improves Endothelial Function, Reduces Blood Pressure and Ischemia-Reperfusion Injury. J Pharmacol Exp Ther 2020; 376:181-189. [PMID: 33214214 DOI: 10.1124/jpet.120.000212] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2020] [Accepted: 11/13/2020] [Indexed: 12/18/2022] Open
Abstract
Multiple clinical and preclinical studies have demonstrated that plasma levels of asymmetric dimethylarginine (ADMA) are strongly associated with hypertension, diabetes, and cardiovascular and renal disease. Genetic studies in rodents have provided evidence that ADMA metabolizing dimethylarginine dimethylaminohydrolase (DDAH)-1 plays a role in hypertension and cardiovascular disease. However, it remains to be established whether ADMA is a bystander, biomarker, or sufficient contributor to the pathogenesis of hypertension and cardiovascular and renal disease. The goal of the present investigation was to develop a pharmacological molecule to specifically lower ADMA and determine the physiologic consequences of ADMA lowering in animal models. Further, we sought to determine whether ADMA lowering will produce therapeutic benefits in vascular disease in which high ADMA levels are produced. A novel long-acting recombinant DDAH (M-DDAH) was produced by post-translational modification, which effectively lowered ADMA in vitro and in vivo. Treatment with M-DDAH improved endothelial function as measured by increase in cGMP and in vitro angiogenesis. In a rat model of hypertension, M-DDAH significantly reduced blood pressure (vehicle: 187 ± 19 mm Hg vs. M-DDAH: 157 ± 23 mm Hg; P < 0.05). Similarly, in a rat model of ischemia-reperfusion injury, M-DDAH significantly improved renal function as measured by reduction in serum creatinine (vehicle: 3.14 ± 0.74 mg/dl vs. M-DDAH: 1.1 ± 0.75 mg/dl; P < 0.01), inflammation, and injured tubules (vehicle: 73.1 ± 11.1% vs. M-DDAH: 22.1 ± 18.4%; P < 0.001). These pharmacological studies have provided direct evidence for a pathologic role of ADMA and the therapeutic benefits of ADMA lowering in preclinical models of endothelial dysfunction, hypertension, and ischemia-reperfusion injury. SIGNIFICANCE STATEMENT: High levels of ADMA occur in patients with cardiovascular and renal disease. A novel modified dimethylarginine dimethylaminohydrolase by PEGylation effectively lowers ADMA, improves endothelial function, reduces blood pressure and protects from ischemia-reperfusion renal injury.
Collapse
Affiliation(s)
- Young Lee
- Indiana Center for Biomedical Innovation, Indianapolis, Indiana (Y.L., Ar.S., J.S.); Indiana University School of Medicine, Indianapolis, Indiana (P.M., D.B., M.U., N.S., Ar.S., J.S.); University of Mississippi Medical Center, Jackson, Mississippi (S.T.Y., Je.S.); and Vasculonics LLC, Indianapolis, Indiana (J.S.)
| | - Purvi Mehrotra
- Indiana Center for Biomedical Innovation, Indianapolis, Indiana (Y.L., Ar.S., J.S.); Indiana University School of Medicine, Indianapolis, Indiana (P.M., D.B., M.U., N.S., Ar.S., J.S.); University of Mississippi Medical Center, Jackson, Mississippi (S.T.Y., Je.S.); and Vasculonics LLC, Indianapolis, Indiana (J.S.)
| | - David Basile
- Indiana Center for Biomedical Innovation, Indianapolis, Indiana (Y.L., Ar.S., J.S.); Indiana University School of Medicine, Indianapolis, Indiana (P.M., D.B., M.U., N.S., Ar.S., J.S.); University of Mississippi Medical Center, Jackson, Mississippi (S.T.Y., Je.S.); and Vasculonics LLC, Indianapolis, Indiana (J.S.)
| | - Mahbub Ullah
- Indiana Center for Biomedical Innovation, Indianapolis, Indiana (Y.L., Ar.S., J.S.); Indiana University School of Medicine, Indianapolis, Indiana (P.M., D.B., M.U., N.S., Ar.S., J.S.); University of Mississippi Medical Center, Jackson, Mississippi (S.T.Y., Je.S.); and Vasculonics LLC, Indianapolis, Indiana (J.S.)
| | - Arshnoor Singh
- Indiana Center for Biomedical Innovation, Indianapolis, Indiana (Y.L., Ar.S., J.S.); Indiana University School of Medicine, Indianapolis, Indiana (P.M., D.B., M.U., N.S., Ar.S., J.S.); University of Mississippi Medical Center, Jackson, Mississippi (S.T.Y., Je.S.); and Vasculonics LLC, Indianapolis, Indiana (J.S.)
| | - Nicholas Skill
- Indiana Center for Biomedical Innovation, Indianapolis, Indiana (Y.L., Ar.S., J.S.); Indiana University School of Medicine, Indianapolis, Indiana (P.M., D.B., M.U., N.S., Ar.S., J.S.); University of Mississippi Medical Center, Jackson, Mississippi (S.T.Y., Je.S.); and Vasculonics LLC, Indianapolis, Indiana (J.S.)
| | - Subhi Talal Younes
- Indiana Center for Biomedical Innovation, Indianapolis, Indiana (Y.L., Ar.S., J.S.); Indiana University School of Medicine, Indianapolis, Indiana (P.M., D.B., M.U., N.S., Ar.S., J.S.); University of Mississippi Medical Center, Jackson, Mississippi (S.T.Y., Je.S.); and Vasculonics LLC, Indianapolis, Indiana (J.S.)
| | - Jennifer Sasser
- Indiana Center for Biomedical Innovation, Indianapolis, Indiana (Y.L., Ar.S., J.S.); Indiana University School of Medicine, Indianapolis, Indiana (P.M., D.B., M.U., N.S., Ar.S., J.S.); University of Mississippi Medical Center, Jackson, Mississippi (S.T.Y., Je.S.); and Vasculonics LLC, Indianapolis, Indiana (J.S.)
| | - Anantha Shekhar
- Indiana Center for Biomedical Innovation, Indianapolis, Indiana (Y.L., Ar.S., J.S.); Indiana University School of Medicine, Indianapolis, Indiana (P.M., D.B., M.U., N.S., Ar.S., J.S.); University of Mississippi Medical Center, Jackson, Mississippi (S.T.Y., Je.S.); and Vasculonics LLC, Indianapolis, Indiana (J.S.)
| | - Jaipal Singh
- Indiana Center for Biomedical Innovation, Indianapolis, Indiana (Y.L., Ar.S., J.S.); Indiana University School of Medicine, Indianapolis, Indiana (P.M., D.B., M.U., N.S., Ar.S., J.S.); University of Mississippi Medical Center, Jackson, Mississippi (S.T.Y., Je.S.); and Vasculonics LLC, Indianapolis, Indiana (J.S.)
| |
Collapse
|
5
|
Jayachandran I, Sundararajan S, Venkatesan S, Paadukaana S, Balasubramanyam M, Mohan V, Manickam N. Asymmetric dimethylarginine (ADMA) accelerates renal cell fibrosis under high glucose condition through NOX4/ROS/ERK signaling pathway. Sci Rep 2020; 10:16005. [PMID: 32994511 PMCID: PMC7525240 DOI: 10.1038/s41598-020-72943-2] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/25/2019] [Accepted: 08/25/2020] [Indexed: 02/07/2023] Open
Abstract
We previously reported that the circulatory level of Asymmetric dimethylarginine (ADMA), an endogenous competitive inhibitor of nitric oxide synthase, was increased in diabetic kidney disease patients. However, the mechanism and the role of ADMA in diabetic kidney injury remain unclear. Hence, our principal aim is to investigate the causal role of ADMA in the progression of renal cell fibrosis under high glucose (HG) treatment and to delineate its signaling alterations in kidney cell injury. High Glucose/ADMA significantly increased fibrotic events including cell migration, invasion and proliferation along with fibrotic markers in the renal cells; whereas ADMA inhibition reversed the renal cell fibrosis. To delineate the central role of ADMA induced fibrotic signaling pathway and its downstream signaling, we analysed the expression levels of fibrotic markers, NOX4, ROS and ERK activity by using specific inhibitors and genetic manipulation techniques. ADMA stimulated the ROS generation along with a significant increase in NOX4 and ERK activity. Further, we observed that ADMA activated NOX-4 and ERK are involved in the extracellular matrix proteins accumulation. Also, we observed that ADMA induced ERK1/2 phosphorylation was decreased after NOX4 silencing. Our study mechanistically demonstrates that ADMA is involved in the progression of kidney cell injury under high glucose condition by targeting coordinated complex mechanisms involving the NOX4- ROS-ERK pathway.
Collapse
Affiliation(s)
- Isaivani Jayachandran
- Department of Vascular Biology, Madras Diabetes Research Foundation & Dr. Mohan's Diabetes Specialities Centre, WHO Collaborating Centre for Non-Communicable Diseases Prevention and Control & ICMR Center for Advanced Research On Diabetes, Chennai, India
| | - Saravanakumar Sundararajan
- Department of Vascular Biology, Madras Diabetes Research Foundation & Dr. Mohan's Diabetes Specialities Centre, WHO Collaborating Centre for Non-Communicable Diseases Prevention and Control & ICMR Center for Advanced Research On Diabetes, Chennai, India
| | - Saravanakumar Venkatesan
- Department of Vascular Biology, Madras Diabetes Research Foundation & Dr. Mohan's Diabetes Specialities Centre, WHO Collaborating Centre for Non-Communicable Diseases Prevention and Control & ICMR Center for Advanced Research On Diabetes, Chennai, India
| | - Sairaj Paadukaana
- Department of Vascular Biology, Madras Diabetes Research Foundation & Dr. Mohan's Diabetes Specialities Centre, WHO Collaborating Centre for Non-Communicable Diseases Prevention and Control & ICMR Center for Advanced Research On Diabetes, Chennai, India
| | - Muthuswamy Balasubramanyam
- Department of Vascular Biology, Madras Diabetes Research Foundation & Dr. Mohan's Diabetes Specialities Centre, WHO Collaborating Centre for Non-Communicable Diseases Prevention and Control & ICMR Center for Advanced Research On Diabetes, Chennai, India
| | - Viswanathan Mohan
- Department of Vascular Biology, Madras Diabetes Research Foundation & Dr. Mohan's Diabetes Specialities Centre, WHO Collaborating Centre for Non-Communicable Diseases Prevention and Control & ICMR Center for Advanced Research On Diabetes, Chennai, India
| | - Nagaraj Manickam
- Department of Vascular Biology, Madras Diabetes Research Foundation & Dr. Mohan's Diabetes Specialities Centre, WHO Collaborating Centre for Non-Communicable Diseases Prevention and Control & ICMR Center for Advanced Research On Diabetes, Chennai, India.
| |
Collapse
|